Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
Tempus AI Stock Jumps, ALERT Trial Results Boost EHR Automation Buzz
10:23am, Wednesday, 01'st Apr 2026
Specifically, the study found a 40% relative increase in life-saving valve procedures and a 27% increase in multidisciplinary heart team evaluations within just 90 days.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatmen
TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?
02:41pm, Tuesday, 31'st Mar 2026
Tempus AI TEM and Doximity DOCS are two well-established players in the Medical Information Systems industry, each with distinct niche. Tempus is focused on advancing precision medicine through artifi
Thermo Fisher Scientific Launches Thermo Scientific Glacios 3 Cryo-TEM
08:30am, Tuesday, 31'st Mar 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduces a next-generation cryogenic transmission electron microscope (cryo-TEM) designed to hel
2 AI Healthcare Stocks to Buy Right Now
06:45am, Tuesday, 31'st Mar 2026
AI-powered drug discovery and development is now a possibility. Artificial intelligence is also able to help caregivers navigate a complex collection of ever-changing treatment options.
Tempus AI: An Attractive Entry Point At Current Prices
01:13am, Tuesday, 31'st Mar 2026
Tempus AI is rated Strong Buy with a $71 12-month price target, reflecting 67% upside after a 60% share price decline. TEM's integrated genomic and clinical data flywheel creates a defensible moat, re
Cathie Wood Dumps $2.1 Million in This 'Magnificent Seven' Stock
11:44am, Friday, 27'th Mar 2026
Cathie Wood's ARK Invest sold shares of Meta Platforms (META) and added to its position in Tempus AI (TEM).The investment firm offloaded 3,578 Meta shares value
Tempus AI Reinforces Market Position With Collaborations in 2026
03:30pm, Thursday, 26'th Mar 2026
TEM expands 2026 reach via strategic collaborations, boosting oncology, diagnostics and AI-driven insights to enhance care and drug development.
Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
12:32pm, Thursday, 26'th Mar 2026
Tempus (TEM) reported earnings 30 days ago. What's next for the stock?
Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Recommendation of “Moderate Buy” from Analysts
02:29am, Thursday, 26'th Mar 2026
Shares of Tempus AI, Inc. (NASDAQ: TEM - Get Free Report) have received an average rating of "Moderate Buy" from the thirteen brokerages that are currently covering the company, Marketbeat reports. On
Tempus AI's Diagnostics and Data Arms Drive Long-Term Growth Story
01:07pm, Monday, 23'rd Mar 2026
Tempus AI's dual-engine model drives $1.27B revenues, with Diagnostics dominating and Data monetization accelerating growth and pricing leverage.
Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.
06:25am, Saturday, 21'st Mar 2026
Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Soci
Tempus AI Advances Clinical Applications and Healthcare Software
10:42am, Monday, 16'th Mar 2026
TEM expands its clinical software push with TIME trial-matching, Tempus Next care intelligence and an upgraded Tempus One AI assistant for providers.
Tempus AI, Inc. $TEM Shares Bought by Bamco Inc. NY
04:23am, Monday, 16'th Mar 2026
Bamco Inc. NY raised its holdings in shares of Tempus AI, Inc. (NASDAQ: TEM) by 53.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. Th
